IFNGR1 and neoplasm: Since the IFN-γ signaling pathway in melanoma cells induces tumor growth arrest and death, mutations of IFNGR1, IFNGR2, JAK1, JAK2, STAT1, and IRF3 lead to insensitivity to anti-tumor IFN-γ activity (37, 38).